|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.01.26 - 08:06
|
DanCann Pharma A/S: No warrants exercised in extraordinary exercise period in connection with delisting (Cision)
|
|
|
COPENHAGEN, Denmark, 13 January 2026 – DanCann Pharma A/S, CVR-no. 39426005 (SS: DANCAN), a Danish medicinal cannabis company listed on Spotlight Stock Market (“DanCann Pharma” or the “Company”) announced on 29 December 2025 that an extraordinary exercise period for a total of 1,224,993 warrants commenced as a result of the Company's application for a delisting. The last day of the extraordinary exercise period was yesterday, and no warrants have been exercised.
No exercise of warrants
As announced on 29 December 2025, a total of 1,224,993 outstanding warrants in the Company issued...
|
|
|
|
|
13.01.26 - 00:36
|
China′s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens (SCMP)
|
|
|
Foreign and mainland Chinese drug makers are fighting for a multibillion-dollar slice of the domestic weight-loss market by slashing prices by as much as 80 per cent, as China faces a worsening obesity crisis.
Competition in the sector, dominated by global pharmaceutical giants Novo Nordisk and Eli Lilly, intensified after both secured obesity-drug approvals in China in 2024. The landscape is set to shift further when the patent on Novo Nordisk's semaglutide expires in March in China, opening......
|
|
|
|
|
|
|
|
|
12.01.26 - 13:21
|
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program (GlobeNewswire EN)
|
|
|
COPENHAGEN, Denmark, January 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....
|
|
|
12.01.26 - 11:09
|
Cancer Drugs Drive Nearly One-Fifth Of Pharma Sales (ZeroHedge)
|
|
|
Cancer Drugs Drive Nearly One-Fifth Of Pharma Sales
The global pharmaceutical industry's revenue is increasingly concentrated in a handful of high-value drug classes, with oncology, diabetes/obesity treatments and immunology leading the charge.
As Statista's Tristan Gaudiat details below, according to estimates from Statista Market Insights, cancer drugs alone generated over $217 billion last year, making oncology the largest therapeutic segment, driving nearly one-fifth (18 percent) of all pharmaceutical sales.
You will find more infographics at Statista
Antidiabetic medicines rank second, with estimated sales of over $85 billion in 2025, contributing 7 percent to global market revenues.
Some of the top-grossing drugs include Merck's Keytruda, an immunotherapy for multiple cancers with almost $30 billion in revenue in 2024, as well as Eli Lilly's Mounjaro and Novo Nordisk's Ozempic/Wegovy, used for diabetes treatment and weight loss, and bringing in more than $10 billion annually for th...
|
|
|
12.01.26 - 10:48
|
Novo Nordisk Buy (DPA-AFX)
|
|
|
HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Novo Nordisk mit einem Kursziel von 400 dänischen Kronen auf "Buy" belassen. Luisa Hector liegt mit ihren Schätzungen für 2030 bei den Dänen am weitesten über dem Konsens. Dies ......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
